By: Dr. Shane Kurth, D.C., BCN
Co-Owner, Radiant Results
Updated September 2026

This post examines the clinical basis of menopause-related joint pain — including the emerging concept of Musculoskeletal Syndrome of Menopause (MSM) — and surveys evidence-based options across the full treatment spectrum, from resistance training and HRT to the emerging role of photobiomodulation. Red light therapy is presented as an adjunct, not a replacement for medical care, with its current evidence base and limitations stated plainly. For diagnosis, hormone management, or rheumatologic evaluation, consultation with a licensed physician or specialist is required.

Medical Disclaimer: This content is for educational purposes only and does not constitute medical advice, diagnosis, or a treatment plan. Menopause-related joint symptoms vary widely and some conditions require urgent specialist evaluation. Readers experiencing severe, worsening, or acutely swollen joints should consult a qualified healthcare provider promptly.

Menopause Joint Pain Relief in Uptown Charlotte: What the Evidence Shows

Estrogen performs specific protective functions in joint tissue — suppressing inflammation, maintaining cartilage integrity, and supporting synovial fluid quality. When estrogen declines during perimenopause, those protections are withdrawn simultaneously. That is the direct physiological mechanism behind menopause joint pain, and it explains why this condition is distinct from ordinary age-related wear. Researchers now recognize this cluster of symptoms as the Musculoskeletal Syndrome of Menopause (MSM). Women in the Charlotte area and beyond have multiple evidence-based relief options — from resistance training and hormone therapy to emerging modalities like red light therapy — and understanding the mechanism is the first step toward effective management.

Key Takeaways

• Menopause-related joint pain is mechanistically distinct from age-related wear. Estrogen decline simultaneously removes joint-protective anti-inflammatory signaling and the hormonal support that maintains cartilage matrix integrity and synovial fluid quality.
• The Musculoskeletal Syndrome of Menopause (MSM) is a formally named clinical entity — not a vague catch-all — encompassing arthralgia, sarcopenia, accelerated OA progression, and frozen shoulder, with prevalence exceeding 70% in midlife women (Wright et al., Climacteric, 2024).
• Resistance training carries the strongest evidence base for symptom management. Hormone replacement therapy directly addresses the root mechanism and is appropriate for many women following physician evaluation. Both are first-line before adjunct modalities.
• Photobiomodulation (red light therapy) has demonstrated pain and disability reduction versus placebo in knee osteoarthritis trials (Oliveira et al., 2024, 10 RCTs, 542 participants). It is classified as an adjunct to established therapies — not a standalone treatment — with certainty of evidence rated as very low by the study authors.
• Differential diagnosis matters. Menopause arthralgia, osteoarthritis, and rheumatoid arthritis share overlapping presentations. Elevated inflammatory markers (CRP, ESR, RF, anti-CCP) or acute joint swelling warrant specialist evaluation, not complementary care.

Why Menopause Causes Joint Pain: The Estrogen-Inflammation Connection

Estrogen performs two distinct protective functions in joint tissue, and perimenopause compromises both at once. First, estrogen suppresses pro-inflammatory signaling. When circulating estrogen falls, inflammatory pathways that estrogen had been actively dampening become upregulated, increasing cytokine-mediated joint irritation. Second, estrogen supports structural joint integrity by maintaining cartilage matrix quality and contributing to the viscosity of synovial fluid — the lubricant that reduces friction between articulating surfaces.

When synovial fluid becomes less viscous — a direct consequence of estrogen withdrawal acting on synovial membrane tissue — joints experience increased friction and inflammatory signaling even before any structural damage is visible on imaging. This explains a frustrating and frequently misunderstood clinical pattern: significant joint pain can coexist with entirely normal X-ray and MRI findings. This mechanism is well-documented in the menopause-arthralgia literature.

The downstream structural consequences accumulate over time. Postmenopausal women show disproportionately higher incidence and severity of osteoarthritis compared to men of the same age. A 2026 systematic review and meta-analysis published in the Journal of Bone and Joint Surgery (PMC12784006) — examining data from 93,021 women — found that muscle and joint symptoms affected 57% of perimenopausal and 59% of postmenopausal women, compared to 40% of premenopausal women. That step change corresponds with the hormonal transition, not with chronological aging.

The timing pattern during perimenopause deserves particular attention. Musculoskeletal symptoms often intensify during the volatile fluctuation phase — before estrogen has fully withdrawn. Estrogen receptor sensitivity in joint tissue appears to respond to the instability of fluctuating levels, not just to absolute decline. Many women who present during this phase have their symptoms attributed to overuse, stress, or early inflammatory arthritis, delaying accurate framing of the problem.

Understanding how red light therapy affects inflammation pathways can provide useful context for why photobiomodulation is being studied as an adjunct in inflammatory musculoskeletal conditions. The evidence base specific to menopause is still developing, as the later section on PBM addresses directly.

Musculoskeletal Syndrome of Menopause: A Recognized Clinical Pattern, Not “Just Aging”

In 2024, orthopedic sports surgeon Dr. Vonda Wright and colleagues published a formal characterization of the Musculoskeletal Syndrome of Menopause in Climacteric (27:5, 466–472). MSM is defined as a recognizable, hormone-driven clinical syndrome encompassing arthralgia, sarcopenia, accelerated osteoarthritis progression, bone density decline, tendinopathy, and adhesive capsulitis (frozen shoulder). These manifestations share a common root: estrogen’s role in maintaining musculoskeletal tissue integrity across multiple tissue types simultaneously.

The prevalence figures from Wright et al. 2024 establish the scale clearly. More than 70% of midlife women will experience musculoskeletal symptoms during the perimenopause-to-postmenopause transition, and approximately 25% will experience symptoms severe enough to cause functional disability. For a substantial proportion of affected women, a plain X-ray or MRI will return unremarkable results, and the underlying hormonal etiology will go unnamed.

This is the diagnostic gap that the MSM framework is designed to address. Practitioners treating women in midlife frequently encounter a recognizable pattern: a woman in her late 40s or early 50s presents with bilateral hand stiffness, one shoulder that has progressively lost range of motion, and achy knees. She has already seen a rheumatologist, completed a Lyme disease panel, been tested for lupus and Sjögren’s, and received normal results throughout. The diagnostic odyssey is real. It stems from the absence of a unifying clinical framework in many generalist practice settings.

Naming this syndrome matters practically. The MSM label shifts the clinical conversation from “that’s just menopause” to an active, treatable hormonal syndrome with specific management strategies. The symptom cluster — arthralgia, myalgia, accelerated OA, bone density loss, frozen shoulder, tendinopathy — does not present identically in every patient, but the hormonal mechanism is consistent enough to guide both investigation and treatment planning.

For support with joint pain relief as part of a broader approach, understanding where red light therapy fits in the evidence hierarchy matters — which the mechanism section below addresses directly.

Which Joints Are Most Affected — and How to Tell It’s Menopause, Not Arthritis

The joints most commonly implicated in menopause-related arthralgia are the knees, hips, lumbar spine, hands (particularly the smaller interphalangeal joints), and shoulders. This distribution reflects both the weight-bearing demand on larger joints and the estrogen receptor density in specific periarticular tissues. Adhesive capsulitis — frozen shoulder — deserves particular mention. Up to 70% of frozen shoulder cases occur in women, and peak incidence clusters within the perimenopausal window.

The clinical pattern of menopause arthralgia differs meaningfully from both osteoarthritis and rheumatoid arthritis, though the overlap creates genuine diagnostic difficulty. Menopause-related joint pain tends to be polyarticular — affecting multiple joints simultaneously — often symmetrical, and frequently migratory. Morning stiffness typically resolves within 30 minutes. Imaging is often unremarkable. Primary OA, by contrast, tends to be more focal and asymmetric, associated with progressive imaging changes, and linked to specific mechanical loading histories.

Rheumatoid arthritis presents with prolonged morning stiffness exceeding one hour, joint swelling that is warm and boggy to palpation, and — critically — elevated inflammatory markers including rheumatoid factor (RF), anti-cyclic citrullinated peptide antibodies (anti-CCP), C-reactive protein (CRP), and erythrocyte sedimentation rate (ESR).

One important complication: perimenopause can unmask previously subclinical rheumatoid arthritis. The hormonal shifts of the transition appear to interact with autoimmune thresholds in some women, meaning that a new RA diagnosis during perimenopause is not coincidental. If inflammatory markers are elevated, or if symptoms include warm, swollen joints, rheumatology evaluation is warranted — not watchful waiting, and not complementary therapy as a first response.

The comparison below is an educational orientation — not a self-diagnostic checklist. A formal diagnosis requires clinical evaluation and laboratory testing by a qualified provider.

This comparison is for educational purposes only. A formal diagnosis requires clinical evaluation and laboratory testing by a qualified provider.

Managing back pain and spinal joint discomfort involves distinct considerations — addressed in a dedicated section below — given the lumbar spine’s particular vulnerability to estrogen-related changes.

Evidence-Based Relief Options: From Resistance Training to HRT

Across interventions studied for menopause-related joint pain, progressive resistance training carries the most consistently strong evidence. Building muscular support around affected joints reduces mechanical load on cartilage and synovial surfaces. Exercise itself also drives down pro-inflammatory cytokine load, combats the sarcopenia that accelerates with estrogen loss, and supports bone mineral density — all simultaneously. Established exercise science and rheumatology literature consistently position resistance training as the first-line recommendation for musculoskeletal symptoms in midlife women. It is the foundation on which any other intervention should be layered.

Hormone replacement therapy addresses the root mechanism of MSM directly. By restoring estrogen levels, it re-establishes the anti-inflammatory and cartilage-protective effects that estrogen withdrawal removed. A 2025 systematic review in Post Reproductive Health by Overton et al. examined HRT’s effects specifically on musculoskeletal pain in menopausal women and reported support for its role in symptom reduction. HRT requires physician evaluation. Contraindications include personal or family history of certain hormone-sensitive cancers, cardiovascular risk factors, and clotting history, among others.

Targeted physical therapy and joint-specific exercise programs complement resistance training by addressing the biomechanical compensation patterns that develop when joint pain goes unmanaged. This is particularly relevant for frozen shoulder and lumbar SI joint dysfunction, where movement restrictions and muscular guarding create secondary dysfunction beyond the primary hormonal process.

Supplement approaches are commonly discussed in this context, with evidence strength varying by agent. Vitamin D and omega-3 fatty acids have the most robust data for anti-inflammatory support in musculoskeletal conditions. Vitamin D deficiency is particularly common in postmenopausal women and independently associated with musculoskeletal pain. NSAIDs provide effective short-term symptomatic relief but carry GI, renal, and cardiovascular risk with long-term use — physician guidance is required for extended use.

For muscle recovery support between active rehabilitation sessions, photobiomodulation is among the emerging adjunct modalities being studied. The evidence is addressed in the following section.

What to Expect: A General Timeline for Menopause Joint Pain Management

This timeline reflects general clinical patterns from study protocols — not a guarantee for any individual patient.

Red Light Therapy for Menopause Joint Pain: What the Evidence Shows

Red light therapy — clinically termed photobiomodulation (PBM) — delivers specific wavelengths of red (~630–660nm) and near-infrared (~810–850nm) light to stimulate cellular energy production through cytochrome c oxidase, a key enzyme in the mitochondrial respiratory chain. This interaction increases ATP output, reduces oxidative stress, and modulates local inflammatory signaling at the cellular level, as documented by Hamblin (2017). Red light penetrates approximately 8–10mm into tissue, reaching superficial layers including skin and surface fascia. Near-infrared light penetrates 2–5cm — reaching joint-adjacent musculature, tendons, and subchondral tissue depending on joint anatomy and body composition.

The OA evidence base, honestly calibrated. A 2024 systematic review with meta-analysis by Oliveira et al., published in Physical Therapy (10 randomized placebo-controlled trials, 542 participants), examined photobiomodulation specifically for knee osteoarthritis. The review found that PBM produced statistically significant reductions in pain intensity and improvements in disability scores versus placebo. The authors rated the certainty of evidence as very low, primarily due to risk of bias in included studies, and explicitly classified PBM as a complement to established therapies — not a standalone treatment. That GRADE rating is not a reason to dismiss the evidence. It is a reason to present it accurately, which this guide does.

The menopause population gap. The Oliveira et al. 2024 review — and the broader PBM joint pain literature — is conducted in OA and general musculoskeletal pain populations, not in perimenopausal women as a specific cohort. The mechanism is biologically plausible for menopause-related arthralgia. MSM is substantially driven by inflammatory upregulation following estrogen withdrawal, and PBM has demonstrated anti-inflammatory effects via the cytochrome c oxidase pathway and reactive oxygen species modulation. The potential for adjunctive benefit in this population is mechanistically coherent. However, head-to-head trial data in perimenopausal women specifically is currently limited as of 2026.

A counterpoint that belongs in an honest guide. A 2023 randomized controlled trial by Jorge et al., published in the Brazilian Journal of Physical Therapy, found that adding PBM to a structured strengthening exercise program produced no incremental benefit over exercise alone in knee OA. This finding does not contradict the Oliveira et al. results — it contextualizes them. PBM appears most impactful when structured exercise is not yet well established, or when used as a recovery adjunct in populations that cannot tolerate full exercise loading. For women already in active, consistent resistance training programs, the independent contribution of red light therapy may be more modest.

Evidence rating for RLT in menopause joint pain: Emerging — biologically plausible with supporting mechanism research and indirect evidence from OA populations; direct clinical trials in perimenopausal women are limited as of 2026.

At Radiant Results, the Dahlia Full Body Medical Grade Light Therapy Bed delivers simultaneous red and near-infrared wavelengths across the full body in 15-minute sessions — covering multiple joint sites simultaneously, rather than targeting a single joint in isolation. For women managing MSM with its characteristic polyarticular presentation — knees, hands, hips, and lumbar spine all symptomatic at once — the full-body delivery format is worth noting, even as the clinical evidence remains early-stage for this specific population.

Menopause Back Pain and the Lumbar Spine: A Closer Look

The lumbar spine is among the joints most meaningfully affected by estrogen decline — and among the least recognized as a hormone-related target. Estrogen receptors are present in intervertebral disc tissue, spinal ligaments, and the sacroiliac joint capsule. As estrogen withdraws, lumbar disc dehydration accelerates, spinal ligament laxity increases, and SI joint pain becomes more prevalent. Treating this pattern like a mechanical back injury — without accounting for the hormonal etiology — often produces unsatisfying clinical results.

Postmenopausal women show higher rates of lumbar facet joint osteoarthritis and SI joint dysfunction than premenopausal counterparts, consistent with the same estrogen-depletion mechanism driving peripheral joint OA. Because this pattern is rarely named in generalist settings, women with perimenopausal lumbar pain frequently cycle through postural assessments, core weakness programs, and imaging studies that return unremarkable results — without a practitioner connecting symptom onset to the hormonal timeline.

Management follows the same evidence hierarchy as peripheral joint pain. Resistance training with a core-stabilization emphasis and targeted physical therapy carry the strongest evidence. HRT’s protective effect on spinal bone density is established. For photobiomodulation applied to the lumbar region, near-infrared light at 2–5cm tissue depth reaches paraspinal musculature and SI joint-adjacent tissue. The same biologically plausible anti-inflammatory mechanism described in the previous section applies — with the same evidence calibration: emerging and adjunct in framing.

Seeking Menopause Joint Pain Relief in Uptown Charlotte

Finding a credible approach to MSM in Uptown Charlotte begins with recognizing what an honest, clinically grounded program looks like. A practitioner or program worth engaging will take a full intake history — connecting symptom onset to hormonal timeline, asking when perimenopause began and how joint symptoms tracked alongside it. It will offer non-pharmaceutical adjunct options alongside, not instead of, appropriate referrals to specialists when red flags are present. And it will have a mechanism for tracking progress objectively rather than relying solely on symptom self-report.

Radiant Results uses the Styku 3D body scanner for objective progress tracking — allowing measurable body composition data to supplement symptom self-report. For women managing MSM alongside other body composition changes common in the menopause transition, an objective baseline matters.

The Dahlia Full Body Medical Grade Light Therapy Bed at the Uptown Charlotte studio delivers simultaneous red and near-infrared wavelengths in 15-minute sessions, with full-body coverage across multiple joint sites in a single session. As the evidence section above makes clear, PBM is presented here as a biologically plausible, early-evidence adjunct — not a replacement for the resistance training and specialist care that anchor any serious MSM management plan.

Practical questions worth asking any Charlotte provider: Does the program include clinical oversight from a credentialed practitioner? Is there an objective way to track progress over time? Is the approach compatible with ongoing hormone therapy or physical therapy — or does it position itself as a standalone solution?

Visit Radiant Results — Uptown Charlotte

Menopause joint pain is undertreated and underrecognized. The $79 New Patient Special at Radiant Results Uptown Charlotte includes an initial session in the Dahlia Full Body Medical Grade Light Therapy Bed and an objective body composition assessment via Styku 3D scanning — an evidence-informed entry point to assess whether red light therapy is an appropriate adjunct for a given individual’s goals and history.

Radiant Results — Uptown Charlotte · 535 Yellowstone Drive, Suite 205, Charlotte, NC 28208

Claim the $79 New Patient Special →

When to See a Specialist: Red Flags That Require Prompt Evaluation

Complementary approaches — including red light therapy — are appropriate for women who have already received a clinical evaluation and have a working diagnosis. They are not a substitute for that evaluation. Certain presentations require prompt specialist attention.

Seek medical evaluation promptly for any of the following:

• Acutely swollen, warm, or red joint(s). This presentation may indicate septic arthritis (a medical emergency), acute inflammatory flare, or crystal arthropathy (gout, pseudogout) — none of which should be managed with watchful waiting or adjunct therapy alone.
• Joint pain accompanied by fever or constitutional symptoms. Unexplained fever with joint pain raises the possibility of systemic inflammatory disease or infectious etiology and requires urgent workup.
• Unintentional weight loss alongside musculoskeletal symptoms. Weight loss in combination with joint pain can be a paraneoplastic presentation and warrants urgent physician evaluation.
• Neurological symptoms. Numbness, tingling, weakness, or bowel/bladder changes alongside back or joint pain may indicate nerve root compression or central nervous system involvement — outside the scope of any musculoskeletal adjunct program.
• Elevated inflammatory markers on prior bloodwork (RF, anti-CCP, ESR, CRP). If lab results already show elevated markers, rheumatology evaluation before pursuing adjunct therapies is appropriate.
• Rapidly worsening symptoms. A pain pattern accelerating in severity or spreading to new joints over days to weeks — rather than fluctuating in the pattern typical of MSM — requires evaluation.
• Prior cancer history. Women with a personal history of hormone-sensitive malignancy should discuss any new musculoskeletal symptom cluster with their oncologist before pursuing hormone-adjacent or systemic therapies.

Red light therapy is not appropriate for everyone. Women who are pregnant, taking photosensitizing medications, have active skin infections or open wounds in the treatment area, carry implanted electronic devices or pacemakers, or have a personal history of active malignancy should consult a qualified healthcare provider before pursuing photobiomodulation. For regulatory context on low-level laser and LED devices, the FDA’s light therapy device guidance provides relevant information.

The goal of this guide is not to route readers away from the medical care they may need — it is to provide the clinical framing that helps them ask better questions and identify when specialist evaluation is the right first step.

Frequently Asked Questions

Does menopause actually cause joint pain, or is it just aging?

Menopause causes joint pain through a specific, documented physiological mechanism distinct from age-related wear. Estrogen actively suppresses pro-inflammatory signaling and maintains cartilage matrix integrity and synovial fluid viscosity. When estrogen declines, both protective functions are simultaneously impaired. A 2026 meta-analysis in the Journal of Bone and Joint Surgery (PMC12784006), examining 93,021 women, found musculoskeletal symptoms affected significantly more perimenopausal and postmenopausal women than premenopausal women — a step change that corresponds to hormonal transition, not chronological aging. The two processes can coexist, but they are not the same.

Which joints hurt most during menopause?

The joints most commonly affected by menopause-related arthralgia are the knees, hips, lumbar spine, hands (particularly the smaller finger joints), and shoulders. Adhesive capsulitis — frozen shoulder — is strongly associated with the perimenopausal window and is frequently overlooked as a hormone-related manifestation. Symptoms often affect multiple joints simultaneously and may shift locations over time, which distinguishes MSM-related arthralgia from the more focal pattern of primary osteoarthritis.

How do I know if my joint pain is from menopause or rheumatoid arthritis?

The distinguishing features are clinical and laboratory-based. Menopause-related arthralgia typically presents with brief morning stiffness (resolving within 30 minutes), normal imaging, normal inflammatory markers, and a temporal relationship to hormonal transition. Rheumatoid arthritis produces prolonged morning stiffness exceeding one hour, warm and boggy joint swelling, and elevated markers including RF, anti-CCP, CRP, and ESR. Perimenopause can unmask previously subclinical RA, so overlap is possible. Elevated markers or joint swelling warrant rheumatology evaluation — not self-diagnosis or adjunct therapy alone.

Will menopause joint pain improve after menopause is complete?

For some women, arthralgia that peaks during perimenopause does improve once estrogen levels stabilize in postmenopause. For others, the structural consequences of estrogen withdrawal — accelerated OA, reduced bone density, sarcopenia — are progressive and do not self-resolve. The trajectory depends significantly on whether active management is in place. Women who implement resistance training, physical therapy, and appropriate medical care during the transition show better long-term functional outcomes than those who wait.

Can red light therapy help with menopause joint pain?

Current evidence supports photobiomodulation as a pain-reducing adjunct in knee osteoarthritis — the joint-degradation mechanism most accelerated by estrogen decline. Oliveira et al. (2024, Physical Therapy, 10 RCTs, 542 participants) found PBM significantly reduced pain and disability versus placebo, though the certainty of evidence was rated very low. No large trials have been conducted specifically in perimenopausal women as a defined cohort. The mechanism is biologically plausible for MSM-related arthralgia, but direct evidence for this population remains limited as of 2026. Red light therapy is best understood as an adjunct to exercise and medical care, not a standalone treatment.

Where can I get medical-grade red light therapy for menopause joint pain in Uptown Charlotte?

Radiant Results Uptown Charlotte offers the Dahlia Full Body Medical Grade Light Therapy Bed — delivering simultaneous red and near-infrared wavelengths across multiple joint sites in 15-minute sessions. First-time visitors can access the $79 New Patient Special, which includes an initial session and a Styku 3D body composition assessment. The studio is located at 201 S Tryon St, Suite 150, Charlotte, NC 28202.

Sources

1. Wright VJ, Schwartzman JD, Itinoche R, Wittstein J. “The musculoskeletal syndrome of menopause.” Climacteric. 2024;27(5):466–472. DOI: 10.1080/13697137.2024.2380363. PMID: 39077777.
2. “Musculoskeletal Manifestations of Perimenopause: A Systematic Review and Meta-Analysis of 93,021 Women.” Journal of Bone and Joint Surgery. 2026. PMC12784006.
3. Oliveira S, Andrade R, Valente C, Espregueira-Mendes J, Silva FS, Hinckel BB, Carvalho Ó, Leal A. “Effectiveness of Photobiomodulation in Reducing Pain and Disability in Patients With Knee Osteoarthritis: A Systematic Review With Meta-Analysis.” Physical Therapy. 2024;104(8):pzae073. DOI: 10.1093/ptj/pzae073. PMID: 38775202.
4. Jorge AES, Dantas LO, Aburquerque-Sendín F, et al. “Photobiomodulation does not provide incremental benefits to patients with knee osteoarthritis who receive a strengthening exercises program: a randomized controlled trial.” Brazilian Journal of Physical Therapy. 2023;27(4):100519. DOI: 10.1016/j.bjpt.2023.100519. PMC10440468.
5. Hamblin MR. “Mechanisms and Applications of the Anti-Inflammatory Effects of Photobiomodulation.” AIMS Biophysics. 2017;4(3):337–361. PMID: 28748217. PMC5523874. (Cited for cytochrome c oxidase mechanism / ATP pathway only.)
6. Overton R, Amini P, Chew A, et al. “The effect of hormone replacement therapy on musculoskeletal pain in menopausal women: A systematic review and meta-analysis.” Post Reproductive Health. 2025. DOI: 10.1177/20533691251403087.
7. Manno R, et al. Menopause joint pain mechanism and clinical management. The Menopause Society, 2026. PMC12915535.